Corcept Therapeutics Incorporated (CORT)

30,39 -0,20 (-0,65%) Börsenschluss: 04:00PM EDT

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
https://www.corcept.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 352

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Joseph K. Belanoff M.D.	Co-Founder, President, CEO & Director	2,43M	N/A	1957
Mr. Atabak Mokari	CFO & Treasurer	863,03k	N/A	1977
Mr. Sean Maduck	President of Endocrinology	1,05M	2,7M	1977
Dr. William Guyer Pharm.D.	Chief Development Officer	1,03M	135k	1968
Mr. Gary Charles Robb	Chief Business Officer & Secretary	1,08M	3,01M	1963
Mr. Joseph Douglas Lyon	Chief Accounting & Technology Officer	N/A	N/A	1978
Dr. Hazel Hunt Ph.D.	Chief Scientific Officer	895,16k	1,75M	1960
Ms. Amy Flood	Chief Human Resources & Communications Officer	N/A	N/A	N/A
Ms. Monica Tellado	President of Emerging Markets	N/A	N/A	1973
Mr. Roberto W. Vieira	President of Oncology	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corporate Governance

Corcept Therapeutics Incorporateds ISS Governance QualityScore, Stand 1. Juni 2024, lautet 6. Die grundlegenden Scores sind Audit: 5, Vorstand: 4, Shareholderrechte: 6, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.